Drugs / GRC 27864
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02179645 | May → Dec 2014 | — | Glenmark Pharmaceuticals Ltd. India | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02361034 Comparator | Jan → Sep 2015 | — | Glenmark Pharmaceuticals S.A. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GRC 27864 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02179645 ↗ |
| Action | Inhibit | “a novel, microsomal Prostaglandin E Synthase-1 Enzyme (mPGES-1) Inhibitor” NCT02179645 ↗ |
| Route | Oral | “Orally Administered GRC 27864” NCT02361034 ↗ |